Biotech

Biotech catch-all — only use if no sub-Sector applies. Editors should pick a sub-Sector first; only fall back to this term when nothing more specific fits. Mirrors the catch-all pattern on the Datatech, Fintech and Disrupts brands.
Medical Devices
Biotech

Bioventus posts 7% Q1 revenue rise and raises 2026 earnings guidance

The Durham-based medical-technology company reported Q1 net sales of $132.1m and lifted its full-year adjusted EPS and cash-flow forecasts.
The Durham-based medical-technology company reported Q1 net sales of $132.1m and lifted its full-year adjusted EPS and cash-flow forecasts.
The Biotech Times Editorial Team  · 
Regulatory Science
Biotech

BridgeBio wins ANVISA approval for acoramidis in ATTR-CM

BEYONTTRA becomes the first near-complete TTR stabiliser approved in Brazil, backed by Phase 3 data showing a 42% cut in cardiovascular mortality and hospitalisation.
BEYONTTRA becomes the first near-complete TTR stabiliser approved in Brazil, backed by Phase 3 data showing a 42% cut in cardiovascular mortality and hospitalisation.
The Biotech Times Editorial Team  · 
Regulatory Science
Biotech

Avalyn Pharma to present AP01 usability and IPF patient data at ATS 2026

Avalyn will show poster data on inhaled pirfenidone nebuliser usability and patient-centred supportive care in pulmonary fibrosis at ATS in Orlando.
Avalyn will show poster data on inhaled pirfenidone nebuliser usability and patient-centred supportive care in pulmonary fibrosis at ATS in Orlando.
The Biotech Times Editorial Team  · 
Biotech

Avalo Therapeutics hits Phase 2 primary endpoint in HS trial

Abdakibart met HiSCR75 at both doses in the 253-patient LOTUS trial, with Avalo now planning a registrational Phase 3 programme in hidradenitis suppurativa.
Abdakibart met HiSCR75 at both doses in the 253-patient LOTUS trial, with Avalo now planning a registrational Phase 3 programme in hidradenitis suppurativa.
The Biotech Times Editorial Team  · 
Biotech

Avacta presents pre|CISION payload data against Enhertu and Datroway

Avacta's Science Day 2026 showcased tumour-selectivity and dual-payload data positioning its PDC platform ahead of approved ADCs.
Avacta's Science Day 2026 showcased tumour-selectivity and dual-payload data positioning its PDC platform ahead of approved ADCs.
The Biotech Times Editorial Team  · 
Bioprocessing
Synthetic Biology
Biotech

AMG Critical Materials beats Q1 2026 guidance on vanadium strength

AMG Critical Materials posted $44m adjusted EBITDA in Q1 2026, ahead of guidance, driven by vanadium gains and the AURA acquisition.
AMG Critical Materials posted $44m adjusted EBITDA in Q1 2026, ahead of guidance, driven by vanadium gains and the AURA acquisition.
The Biotech Times Editorial Team  · 
Biotech

Actuate Therapeutics names Martin Huber to board of directors

The NASDAQ-listed oncology biotech has appointed the former Mersana Therapeutics CEO as an independent director to support elraglusib's path to registration studies.
The NASDAQ-listed oncology biotech has appointed the former Mersana Therapeutics CEO as an independent director to support elraglusib's path to registration studies.
The Biotech Times Editorial Team  · 
Biotech

Tacalyx raises €11m to advance TACA-targeting ADC TCX-201 to clinic

The Berlin biotech selected TCX-201 as its first clinical candidate and targets a CTA filing in 2027 for gastrointestinal and solid tumours.
The Berlin biotech selected TCX-201 as its first clinical candidate and targets a CTA filing in 2027 for gastrointestinal and solid tumours.
The Biotech Times Editorial Team  · 
Subscribe to Biotech